Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Treatment Resistant Depression
Sponsor: Axsome Therapeutics, Inc.
Terminated
This study was terminated once overall program objectives were met.
Other terminated trials from Axsome Therapeutics, Inc.
- Agitation in Patients With Dementia of the Alzheimer's Type · Phase PHASE3 · Apr 2025
- Excessive Sleepiness · Phase PHASE4 · Apr 2024
More terminations from Axsome Therapeutics, Inc.
Other Major Depressive Disorder trials with similar outcome
Listed as NCT04634669, this PHASE2 trial focuses on Major Depressive Disorder and Treatment Resistant Depression and remains terminated or withdrawn. Sponsored by Axsome Therapeutics, Inc., it has been updated 10 times since 2020, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Apr 2023 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jul 2022 — Jan 2023 [monthly]
Completed PHASE2
Status: Enrolling By Invitation → Completed
-
Oct 2021 — Jul 2022 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Enrolling By Invitation PHASE2
Status: Recruiting → Enrolling By Invitation
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Axsome Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .